Physician profile
Daniel E Krampitz
NPI 1104922988
$9,070.28
in general payments reported to CMS, 2019-2025
66 companies · $2,492 in 2025
The $2,492 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $405 · 2021: $465 · 2022: $1,189 · 2023: $1,890 · 2024: $2,091 · 2025: $2,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,471.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.11 | 2021-2025 | |
| Ucb, INC. | $625.71 | 2019-2025 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $604.55 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $511.14 | 2019-2025 | |
| Argenx US, INC. | $470.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $416.36 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $402.29 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $311.09 | 2020-2025 | Daybue, Nuplazid |
| Merz Pharmaceuticals, LLC | $305.17 | 2023-2025 | Xeomin |
| Sk Life Science, INC. | $294.11 | 2022-2024 | Xcopri |
| Genentech USA, INC. | $245.51 | 2019-2023 | Enspryng, Ocrevus |
| Grifols USA, LLC | $206.39 | 2020-2025 | Gamunex-C |
| Vanda Pharmaceuticals INC. | $201.22 | 2025 | Ponvory |
| Sunovion Pharmaceuticals INC. | $170.85 | 2019-2022 | |
| Lilly USA, LLC | $168.76 | 2019-2025 | Amyvid, Emgality, Kisunla |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Krampitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.